Waters Corporation and Sartorius have partnered to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.
The partnership will implement the BioAccord LC-MS System from Waters as a new bioprocess analyser with data connectivity to Sartorius’ Ambr multi-parallel bioreactor systems to deliver mass spectral information on drug substances, related analytes and cell culture media.
At a ~10% CAGR from 2020 to 2025, biopharmaceuticals is the fastest-growing segment of the overall pharmaceutical market, according to a report by Evaluate Pharma. Fueling this growth is the unprecedented rate at which highly complex new biologics are coming to market. As a consequence, biopharmaceutical manufacturers are requiring more upstream analytical data than ever about drug product attributes and bioprocessing efficiency to enable the development of new, better, and more affordable medicines.
“Waters and Sartorius share a commitment to biopharmaceutical customers to solve their problems with the very best process and analytical tools,” said Davy Petit, Senior Director of Global Pharmaceutical and Biomedical Research Business, Waters Corporation. “Clone selection and process development can benefit significantly from at-line versatile mass spectrometry data which can help bioprocess engineers accelerate workflows and increase confidence in making critical decisions. The combination of our technology in the hands of bioprocess scientists, alongside the well-established Sartorius Ambr bioreactor systems installed-base, can significantly reduce the development timeline for delivery of medicines and vaccines.”
“The combination of Ambr and the easy-to-use at-line Waters BioAccord LC-MS System will save bioprocess scientists substantial time and accelerate clone selection and upstream process development,” said Mario Becker, Head of Product Management Cell Culture Technologies at Sartorius. “The closer we can bring fundamentally important MS data to the point where it is needed, and the more Ambr samples that can be tested for quality attributes, the better we can provide bioprocess scientists a more complete picture of drug product quality at any point during cell-line, media, and process development. Eventually, we can envisage such process control, monitoring and product quality testing being fully integrated into the manufacturing environment.”
Biological drugs are made by living cells in bioreactors like the Sartorius Ambr high throughput bioreactor system. At the conclusion of the cell culture process, the proteins are separated from the cell residue and samples are sent to a central laboratory to await testing by analytical scientists using specialist liquid chromatography-mass spectrometry (LC-MS) instruments. It’s not uncommon for the process to stretch across two to four weeks or more depending on the workload, equipment availability, priorities, and staffing levels of the central analytical laboratory.
The combined offering from Sartorius and Waters aims to shorten the process from what can take over a month to two days or less, while giving more control to bioprocess scientists to obtain robust mass spectrometry data for drug substance and cell culture media samples.
The range of Sartorius Ambr multi-parallel bioreactors has been developed to take scientists through the early steps of their upstream process from cell selection, through to process optimisation. The Waters BioAccord System is a small footprint LC-MS instrument designed as an easy-to-operate, at-line benchtop bioprocess analyzer. Its pre-defined analytical methods, guided workflows, auto-calibration, and auto-tuning features allow those without any mass spectrometry experience to obtain high-quality mass spectral data within minutes.